Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Boosted by Kestra Investment Management LLC

Kestra Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 616 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. Kestra Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $648,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $26,000. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $33,000. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Trading Down 0.6 %

Regeneron Pharmaceuticals stock opened at $750.22 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $82.44 billion, a P/E ratio of 18.57, a P/E/G ratio of 2.89 and a beta of 0.15. The company’s fifty day simple moving average is $905.64 and its 200-day simple moving average is $1,019.64.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.